Matteo Morotti
Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer
Morotti, Matteo; Bridges, Esther; Valli, Alessandro; Choudhry, Hani; Sheldon, Helen; Wigfield, Simon; Gray, Nicki; Zois, Christos E.; Grimm, Fiona; Jones, Dylan; Teoh, Eugene J.; Cheng, Wei-Chen; Lord, Simon; Anastasiou, Dimitrios; Haider, Syed; McIntyre, Alan; Goberdhan, Deborah C. I.; Buffa, Francesca; Harris, Adrian L.
Authors
Esther Bridges
Alessandro Valli
Hani Choudhry
Helen Sheldon
Simon Wigfield
Nicki Gray
Christos E. Zois
Fiona Grimm
Dylan Jones
Eugene J. Teoh
Wei-Chen Cheng
Simon Lord
Dimitrios Anastasiou
Syed Haider
Professor Alan McIntyre ALAN.MCINTYRE@NOTTINGHAM.AC.UK
PROFESSOR OF MOLECULAR ONCOLOGY
Deborah C. I. Goberdhan
Francesca Buffa
Adrian L. Harris
Abstract
Tumor hypoxia is associated with poor patient outcomes in estrogen receptor-α–positive (ERα+) breast cancer. Hypoxia is known to affect tumor growth by reprogramming metabolism and regulating amino acid (AA) uptake. Here, we show that the glutamine transporter, SNAT2, is the AA transporter most frequently induced by hypoxia in breast cancer, and is regulated by hypoxia both in vitro and in vivo in xenografts. SNAT2 induction in MCF7 cells was also regulated by ERα, but it became predominantly a hypoxia-inducible factor 1α (HIF-1α)–dependent gene under hypoxia. Relevant to this, binding sites for both HIF-1α and ERα overlap in SNAT2’s cis-regulatory elements. In addition, the down-regulation of SNAT2 by the ER antagonist fulvestrant was reverted in hypoxia. Overexpression of SNAT2 in vitro to recapitulate the levels induced by hypoxia caused enhanced growth, particularly after ERα inhibition, in hypoxia, or when glutamine levels were low. SNAT2 up-regulation in vivo caused complete resistance to antiestrogen and, partially, anti-VEGF therapies. Finally, high SNAT2 expression levels correlated with hypoxia profiles and worse outcome in patients given antiestrogen therapies. Our findings show a switch in the regulation of SNAT2 between ERα and HIF-1α, leading to endocrine resistance in hypoxia. Development of drugs targeting SNAT2 may be of value for a subset of hormone-resistant breast cancer.
Citation
Morotti, M., Bridges, E., Valli, A., Choudhry, H., Sheldon, H., Wigfield, S., Gray, N., Zois, C. E., Grimm, F., Jones, D., Teoh, E. J., Cheng, W.-C., Lord, S., Anastasiou, D., Haider, S., McIntyre, A., Goberdhan, D. C. I., Buffa, F., & Harris, A. L. (2019). Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer. Proceedings of the National Academy of Sciences, 116(25), 12452-12461. https://doi.org/10.1073/pnas.1818521116
Journal Article Type | Article |
---|---|
Acceptance Date | May 9, 2019 |
Online Publication Date | May 31, 2019 |
Publication Date | Jun 18, 2019 |
Deposit Date | Dec 17, 2020 |
Publicly Available Date | Apr 23, 2021 |
Journal | Proceedings of the National Academy of Sciences |
Print ISSN | 0027-8424 |
Electronic ISSN | 1091-6490 |
Publisher | National Academy of Sciences |
Peer Reviewed | Peer Reviewed |
Volume | 116 |
Issue | 25 |
Pages | 12452-12461 |
DOI | https://doi.org/10.1073/pnas.1818521116 |
Keywords | Multidisciplinary |
Public URL | https://nottingham-repository.worktribe.com/output/5154493 |
Publisher URL | https://www.pnas.org/content/116/25/12452 |
Files
12452.full
(2.6 Mb)
PDF
You might also like
NANOG controls testicular germ cell tumour stemness through regulation of MIR9-2
(2024)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search